GSK plc (LON:GSK) Insider Buys £7,820.75 in Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker purchased 545 shares of the stock in a transaction dated Friday, June 20th. The stock was acquired at an average price of GBX 1,435 ($19.53) per share, for a total transaction of £7,820.75 ($10,646.27).

GSK Trading Up 0.5%

LON:GSK traded up GBX 7 ($0.10) during trading hours on Tuesday, reaching GBX 1,410 ($19.19). 13,563,702 shares of the company were exchanged, compared to its average volume of 14,526,118. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The firm has a market cap of £57.22 billion, a price-to-earnings ratio of 22.78, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,242.50 ($16.91) and a 52-week high of GBX 1,678.68 ($22.85). The stock has a 50 day simple moving average of GBX 1,429.79 and a 200 day simple moving average of GBX 1,414.34.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts predict that GSK plc will post 175.980975 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Shore Capital restated a "buy" rating on shares of GSK in a research report on Wednesday, April 30th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research report on Friday, March 28th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of GBX 1,862.50 ($25.35).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.